https://orcid.org/0000-0001-7978-1652
References
- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583–596.
- Hassan H, Anwer F, Javaid A, et al. Progress in research: daratumumab improves treatment outcomes of patients with AL amyloidosis. Crit Rev Oncol Hematol. 2021;165:103435.
- Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385:46–58.
- Comenzo R. Reduction in absolute involved free light chain and difference between involved and uninvolved free light chain is associated with prolonged major organ deterioration progression-free survival in patients with newly diagnosed AL amyloidosis receiving bortezomib, cyclophosphamide, and dexamethasone with or without daratumumab: results from andromeda. ASH; 2020 [cited 2021 Nov 21]. Available from https://ash.confex.com/ash/2020/webprogram/Paper137582.html
- Sanchorawala V. Health-related quality of life in patients with AL amyloidosis treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone: results from the Phase 3 andromeda study. ASH; 2020 [cited 2021 Nov 21]. Available from: https://ash.confex.com/ash/2020/webprogram/Paper139438.html
- City of Hope Medical Center. A multicenter, open-label, single arm, Phase II study of daratumumab as consolidation/maintenance therapy after autologous stem cell transplantation in patients with multiple myeloma. clinicaltrials.gov. Clinical Trial Registration NCT03346135; 2021 Feb 10 [cited 2021 Nov 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT03346135
- Daratumumab and Hyaluronidase. Lexi-drugs online [database on the Internet]. Hudson (OH): Lexicomp, Inc.; 2022 [updated 2022 Jan 11; cited 2022 Jan 19]. Available from: http://online.lexi.com. Subscription required to view.
- Weill Medical College of Cornell University. Daratumumab, pomalidomide, and dexamethasone (DPD) in relapsed/refractory light chain amyloidosis patients previously exposed to daratumumab. clinicaltrials.gov. Clinical Trial Registration NCT04270175; 2021 Jun 23 [cited 2021 Nov 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT04270175
- M.D. Anderson Cancer Center. A safety study of daratumumab, ixazomib, and dexamethasone in AL amyloidosis. clinicaltrials.gov. Clinical Trial Registration NCT03283917; 2021 Feb 12 [cited 2021 Nov 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT03283917